From Due Diligence to Deal: A Five-Step Framework for Evaluating a Chinese Beauty Company
China’s C-Beauty sector is consolidating fast — 74% of top-50 brands are still growing while long-tail brands collapse. This is a practical framework for PE/VC investors, cross-border M&A teams and international law firms to evaluate Chinese beauty targets rigorously before signing.
Contents
1. Why C-Beauty Is Entering Its M&A Prime
For the past decade, China’s beauty industry was a story of volume: thousands of new brands launched every year, social-media channels minted overnight hits, and investors chased growth at almost any price. The 2026 China Beauty Industry Development White Paper confirms that this era is over. In 2025, China’s omni-channel beauty retail reached RMB 1.1 trillion, but growth moderated to 2.83% — the slowest annual rate in the sector’s modern history. Nearly 27,000 brands exited the market, and domestic brands’ share climbed to 57.37%, surpassing international incumbents for the first time.
still posted positive growth
ranked below #500
in a single year
These numbers point to one conclusion: C-Beauty is bifurcating. A small cohort of scaled, R&D-led, brand-driven companies is pulling away from a massive tail of operators that lack real product differentiation, compliant manufacturing or sustainable economics. For overseas investors and strategic acquirers, this creates an unusually attractive moment — but also an unusually dangerous one.
The high-quality targets genuinely exist. Companies such as Botanee (owner of Winona/薇诺娜), Yatsen (Perfect Diary parent) and Chando Group now hold hundreds of patents, run in-house R&D centers, and compete head-to-head with L’Oréal and Estée Lauder in premium segments. But the pipeline is also cluttered with companies that look investable on a pitch deck yet conceal weak IP ownership, opaque related-party transactions, unregistered production capacity, or unresolved regulatory penalties.
The key implication for international dealmakers: In a market where the gap between winners and losers is widening by the quarter, a systematic, locally verified due diligence process is no longer a formality — it is the single biggest determinant of whether an acquisition or partnership creates long-term value or ends in a write-down.
Cross-border deals add a layer of complexity that most Western due diligence playbooks are not designed to handle. China’s corporate registration system (administered by SAMR, the State Administration for Market Regulation), its IP registry (CNIPA), its court ruling database, and its tax and invoice systems all operate in Chinese, through fragmented official portals, and often require physical document retrieval or on-site verification. Information that a Western analyst can pull from a single registry (say, UK Companies House or EU Orbis) may require consulting five or six separate Chinese sources — each with its own access rules, update cycles and document formats.
The framework below is built to navigate that complexity. It breaks a Chinese beauty-company due diligence into five sequential, verifiable steps, each mapped to a specific Chinese government data source and a specific deliverable an international deal team can request.
2. The Five-Step Due Diligence Framework
The framework is designed to be executed sequentially, with each step building on the verified facts of the previous one. Skipping ahead — for example, starting with financials before confirming the target’s legal identity — is the most common reason cross-border deals hit avoidable surprises.
Identity Verification — Does the Company Legally Exist?
Objective: Confirm that the entity you are negotiating with is a legally registered, currently active Chinese company, and that the information in your deal documents matches the official government record.
Begin with an Official Enterprise Credit Information Report issued by the National Enterprise Credit Information Public System (NECIPS, 国家企业信用信息公示系统). This is the Chinese government’s authoritative record of the company. It shows the Unified Social Credit Code, registered address, legal representative, registered capital, business scope, establishment date and current operating status (active / deregistered / revoked / listed as abnormal).
- Red flag: The registered address on the contract is a “virtual office” or co-working space that does not match the production or R&D facilities shown in the management presentation.
- Red flag: The company is already on the “List of Abnormal Operations” (经营异常名录) — typically caused by failure to file annual reports or an unreachable registered address.
- Red flag: The business scope does not include cosmetics manufacturing or cosmetics wholesale — a common sign that the counterparty is a trading company masquerading as a brand operator.
Ownership Penetration — Who Really Controls the Company?
Objective: Identify the ultimate beneficial owner (UBO), map the full shareholder structure, and surface related-party entities, hidden co-investors and potential conflicts of interest.
A company’s official SAMR filing only shows direct shareholders. To understand who ultimately controls the target — and whether those controllers have stakes in competing or risky businesses — you need an Executive & Shareholder Risk Report, which traces directors, supervisors and senior management (“董监高”) through all their cross-investments and board seats.
- Does the “founder” shown on the cap table actually control the company, or is there an undisclosed nominee arrangement?
- Are there sister entities (factories, distributors, ingredient suppliers) that should be consolidated or at least disclosed as related-party transactions?
- Have any directors or shareholders been involved in previously bankrupt, deregistered or penalized cosmetics companies?
- Has the company undergone frequent changes of legal representative or registered capital in the 24 months before the deal — a common pre-deal restructuring signal?
In the C-Beauty sector in particular, it is common for a single founder to control four to six related entities (brand owner, operating company, manufacturing arm, two e-commerce shops, an IP holding vehicle). Missing any one of them means missing both risk and value.
Legal & Regulatory Risk Scan — Any Time Bombs in the Court Records?
Objective: Uncover ongoing litigation, administrative penalties, customs issues, product recalls, dishonest-judgment (失信被执行人) records and IP disputes that could impair value post-acquisition.
Chinese court records are publicly accessible but fragmented across four databases: China Judgements Online (裁判文书网), the Enforcement Information Disclosure Platform (执行信息公开网), Credit China (信用中国), and the SAMR penalty database. A systematic scan should cover:
- Commercial litigation: Breach-of-contract disputes with distributors, suppliers or former executives.
- IP litigation: Trademark squatting disputes, patent infringement suits (either as plaintiff or defendant), copyright cases against influencers or copycat brands.
- Administrative penalties: NMPA penalties for substandard products, false advertising, unregistered new ingredients, or GMP non-compliance.
- Dishonest-judgment records (失信): The company or its legal representative being on the “laolai” list — a serious red flag that affects banking, customs and government procurement.
In 2024-2025 alone, NMPA and local regulators withdrew or cancelled registrations for thousands of cosmetic products that failed safety assessments or claimed unproven efficacy. A target whose hero SKU is currently under regulatory review is not automatically disqualified, but the contingent liability must be priced into the deal.
Financial & Tax Due Diligence — Are the Numbers Real?
Objective: Cross-check management-reported revenue, margins and tax compliance against third-party data (VAT invoices, tax filings, public bidding records).
For privately held Chinese companies, audited financial statements (when available) are rarely the complete picture. Revenue is often booked across multiple related entities; Tmall/Douyin sales may flow through a separate e-commerce subsidiary; promotional spending may be routed through third-party marketing agencies to inflate top-line GMV while masking true contribution margin.
The most reliable cross-check available to foreign investors is a Financial & Tax Credit Report (财税版信用报告), which pulls VAT-filing data, invoice issuance history, tax payment status, social-insurance contributions and banking/credit records from official tax and third-party credit databases. This allows you to triangulate management’s numbers against data the company has already reported to the Chinese government — which is far harder to restate retroactively.
- Does VAT-invoice revenue roughly reconcile with the revenue shown in the data room? A 10-15% variance is common; a 40%+ variance suggests significant off-books activity.
- Are there any outstanding tax arrears, abnormal VAT invoice patterns, or unresolved transfer-pricing issues with related entities?
- Does employee social-insurance headcount match the number of employees claimed in pitch materials?
IP & Technology Asset Inventory — Does the Brand Actually Own Its “Magic”?
Objective: Verify that the patents, trademarks, copyrights and key ingredients the valuation rests on are registered, valid and owned by the target entity — not by the founder personally or by an unrelated party.
This step is covered in detail in our dedicated IP piece, but for deal purposes three checks are non-negotiable: (1) a full CNIPA search covering invention patents, utility models and design patents; (2) a China Trademark Office (CTMO) search across all 45 Nice classes relevant to beauty (particularly Classes 3, 5, 35 and 44), including Madrid Protocol international registrations; (3) a Patent Register Copy (专利登记簿副本) obtained directly from CNIPA showing current legal status, licensing and pledges.
Common traps in C-Beauty deals include: trademarks registered in the founder’s personal name rather than the operating company; core formulation patents that are actually utility-model or design patents (not invention patents); trademarks registered only in Class 3 while the brand is already selling functional foods or medical-aesthetic devices; and patents that have been pledged as collateral for bank loans without being disclosed.
3. Case Study: What Mao Geping Reveals About Premium C-Beauty
Mao Geping (毛戈平) is one of the most instructive case studies in contemporary C-Beauty — and a textbook example of why a multi-dimensional due diligence process matters. The brand, founded by legendary makeup artist Mao Geping in 2000, has built a distinctive positioning around haute Chinese aesthetics, with a heavy focus on premium department-store counters and a signature “Oriental contouring” technique.
Mao Geping — Premium C-Beauty’s Quiet Breakout
The brand’s trajectory illustrates the kind of high-quality target international acquirers should be paying attention to — and the specific IP and channel assets that must be verified during due diligence.
Top 100 (2025)
(≈ USD 700M)
beauty brand in ranking
Mao Geping’s premium positioning is not just marketing. It rests on three verifiable pillars: a high-margin offline counter network (a moat most C-Beauty DTC brands cannot replicate), an in-house makeup academy that produces a steady pipeline of trained beauty advisors (a talent asset largely invisible from a financial statement), and a carefully curated portfolio of “Eastern aesthetic” trademarks and design patents covering its signature packaging colors, brush shapes and product forms.
Due diligence lesson: For a brand like Mao Geping, a standard financial audit would tell you only part of the story. A rigorous acquirer must also verify: (a) the trademark coverage of the founder’s name and likeness in China and key export markets; (b) ownership of the distinctive product and packaging designs that constitute the brand’s visual identity; (c) employment and non-compete arrangements with the national network of makeup artists who deliver the in-counter experience; (d) lease terms and renewal rights on the premium counter locations that anchor the distribution model. These are the assets that actually justify a premium multiple — and they are invisible unless an investor looks beyond the P&L.
4. From Report to Deal: Turning Data Into Decisions
Due diligence is not an end in itself. The point is to convert verified information into three concrete deal outputs: a defensible valuation, an appropriate deal structure, and a clear 100-day integration plan. Here is how each step of the framework feeds those outputs:
| Finding | What It Usually Means | Deal Action |
|---|---|---|
| Abnormal-operations listing or recent address hopping | Governance instability or potential shell-company behavior | Walk away, or require full remediation and escrow holdback of 20%+ |
| Undisclosed related-party factories or distributors | Transfer-pricing or inflated-margin risk | Restate financials consolidating related entities; price on adjusted EBITDA |
| Active IP litigation against core hero SKU | Potential injunction risk on flagship product | Condition closing on settlement or carve out SKU with price adjustment |
| Trademarks held in founder’s personal name | Post-deal brand-ownership risk | Require assignment to operating entity before closing (condition precedent) |
| Material tax or social-insurance underpayment | Contingent tax liability; possible reputational risk | Tax indemnity from seller + specific escrow for 24-36 months |
| Strong patent portfolio + multiple SCI-published R&D papers | Genuine R&D capability — rare in C-Beauty | Consider earn-out tied to new-patent filings or key-researcher retention |
The notarization step that most acquirers miss. When you request key corporate documents (business license, credit report, IP register copies), insist that they be apostilled or notarized for cross-border use. A document sealed by a Chinese notary public and (where applicable) apostilled under the Hague Convention — which entered into force for China on November 7, 2023 — carries a presumption of authenticity that is enormously helpful when the documents are later submitted to your home-country regulator, your legal counsel, or your investment committee.
For international acquirers without a local China team, assembling all five streams of data from separate government portals, then translating and reconciling them, is typically a 6–10 week effort even with local counsel. A purpose-built China business intelligence provider can collapse that timeline to 5–10 business days by pulling official reports directly and synthesizing them into a single, English-language decision document aligned to each step of the framework.
5. Pre-Signing Due Diligence Checklist
Before wiring funds or signing an SPA, confirm that you have obtained and reviewed all of the following items. Every item on this list is obtainable from official Chinese government sources through a properly authorized verification process.
✓ Minimum Document Checklist for a C-Beauty Acquisition or Strategic Partnership
- Official NECIPS Enterprise Credit Report (latest filing)
- Full ownership-structure penetration to ultimate beneficial owners
- Director/Supervisor/Executive Risk Report with cross-investment mapping
- Court-record and enforcement-record search (3-year lookback)
- NMPA cosmetic product filing/registration certificates for core SKUs
- Cosmetics Production License and on-site GMP status
- Financial & Tax Credit Report with VAT-filing reconciliation
- CNIPA patent register copies for all asserted patents
- CTMO trademark search across all 45 Nice classes + Madrid registrations
- Social-insurance and employee headcount verification
- Related-party transaction schedule (provided by seller, cross-checked)
- Apostilled/notarized copies of key corporate documents
Warning: If a Chinese counterparty pushes back on any of these requests with the line “this is not standard in China” or “we cannot share this because of Chinese law,” treat it as a yellow flag at best. All the documents above are legally obtainable either as public records or with the target company’s own authorization. Legitimate, well-run Chinese beauty companies — the kind you actually want to partner with — are accustomed to providing them.
C-Beauty’s consolidation phase is one of the most interesting M&A windows in global consumer goods today. The companies that survive this cycle will define China’s beauty market for the next decade, and many of them will become global brands in their own right. But the gap between a real C-Beauty champion and a business that simply looks good on a pitch deck is wider than it has ever been. Closing that gap is the entire purpose of due diligence — and in China, due diligence starts with verified, government-sourced data, not with management presentations.
Build Your China Beauty Deal Book on Verified Data
ChinaBizInsight provides official enterprise credit reports, executive and shareholder risk reports, financial & tax reports, and intellectual-property verification — all sourced directly from Chinese government registries and delivered in English. Whether you are screening a single target or running a competitive process across multiple Chinese beauty brands, we can serve as your dedicated on-the-ground verification partner. Contact our deal team to scope a due diligence package tailored to your transaction timeline, or explore our full report catalogue.
References
- iResearch & CBO Media, 2026 China Beauty Industry Development White Paper (2026 release).
- WWD Beauty Inc., “The Top 100 Beauty Companies 2025,” wwd.com/beauty-industry-news.
- State Administration for Market Regulation (SAMR), National Enterprise Credit Information Public System: gsxt.gov.cn.
- National Medical Products Administration (NMPA), Cosmetics Registration & Filing Database: nmpa.gov.cn.
- China National Intellectual Property Administration (CNIPA), Patent Register & Trademark Search: cnipa.gov.cn.
- Hague Convention of 5 October 1961 Abolishing the Requirement of Legalisation for Foreign Public Documents — People’s Republic of China accession (effective 7 November 2023), Hague Conference on Private International Law.
ChinaBizInsight
Your strategic bridge to transparent business in China.